The goal of this activity is for learners to be better able to interpret the evidence of available and emerging therapies for relapsed/refractory multiple myeloma (R/R MM) and implement personalized treatment strategies into clinical practice.
- Provider:Medscape, LLC
- Activity Link: https://www.medscape.org/viewarticle/1000082
- Start Date: 2024-02-20 06:00:00
- End Date: 2024-02-20 06:00:00
- Credit Details: IPCE Credits: 0.5 hours
AMA PRA Category 1 Credit™️: 0.5 hours
Nursing: 0.5 hours
Pharmacy: 0.5 hours - MOC Credit Details: ABIM - 0.5 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: Source: Janssen (Any division) - Amount: 33386.0 - Is Kind Support: False Source: Karyopharm - Amount: 25040.0 - Is Kind Support: False Source: legend biotech - Amount: 16693.0 - Is Kind Support: False Source: Sanofi - Amount: 25040.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Hematology, Medical Oncology
Subscribe
Login
0 Comments
Oldest